Virpax realigns board classes: Ruskin moves to Class I; quorum cut to 34%

Virpax Pharmaceuticals, Inc.

Director Barbara Ruskin resigned from Class III and was appointed to Class I, effective June 5, 2023.
Her term now extends to the 2025 annual meeting (previously 2024).
Bylaws amended to reduce quorum requirement to 34% of voting power at stockholder meetings.

Key facts

Extracted from this filing and checked against the source text.

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

Virpax Pharmaceuticals, Inc.: Amended quorum requirement to 34% voting power of shares issued and entitled to vote (effective 2023-06-05).

Change: bylaw amendment
Effective: 2023-06-05

Exact text from the filing

On June 5, 2023, the Company’s Board of Directors amended the Company’s by-laws, effective immediately in order to amend the quorum requirement of ninth paragraph of Article I, Section 1.6 of the by-laws, such that thirty-four percent (34%) in voting power of shares of the capital stock of the Company issued and entitled to vote at the meeting, present in person or present by means of remote communication in a manner, if any , shall constitute a quorum for the transaction of business at all meetings of the stockholders.

View on SEC.gov

Browse all governance changes →

Source: SEC EDGAR

accession 0001213900-23-047180

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.